Q-omics provides the consensus-scored ATP7B profile across patient tissues and cancer cell-line models. ATP7B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ATP7B is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, ATP7B RNA expression shows 20,491 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where ATP7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP7B survival associations across molecular data types. ATP7B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP7B RNA expression–survival associations across cancer types. High ATP7B expression shows unfavorable associations in DLBC and ESCA, but favorable associations in KIRC, BRCA, LGG and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ATP7B RNA expression.
This table summarizes ATP7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ATP7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP7B shows lower tumor expression in THCA and higher tumor expression in COAD, KIRC, UCEC, BRCA and STAD. The COAD box plot shows higher ATP7B RNA expression in tumor versus normal tissue (log2 FC = +1.517, t-test p < 0.001).
This table shows molecular features associated with ATP7B in patient tissues and cancer cell lines. In patient samples, ATP7B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
